The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Itacitinib plus alemtuzumab for patients with T-PLL
Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights data coming from a Phase IB study of itacitinib combined with alemtuzumab in patients with T-cell prolymphocytic leukemia (T-PLL). To date, alemtuzumab has been the most effective therapy available for patients with T-PLL, although responses are not durable. In this study, patients initially treated with single agent itacitinib reported improvements in symptoms including rash and appetite. Following the addition of alemtuzumab, a high overall response rate (ORR) of 88% was observed in newly diagnosed patients, and an ORR of 57% in previously treated patients. A future study of the combination therapy, without the initial 2-week single agent itacitinib, is planned. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Consulting: AbbVie, Agios, Daiichi Sankyo, Genentech, Jazz, Liberum, Novartis, Pfizer, Pinot Bio, Sanofi-Aventis, Servier
Grant/Research Support: AbbVie, Amgen, Ascentage, Astellas, Astex, AstraZeneca, BMS, Celgene, Cellenkos, Cyclacel, Delta-Fly, Genentech, Genfleet, Glycomimetics, Iterion, Jazz, Pfizer, Pulmotech, Regeneron
Speaker’s Bureau: Cure, Hikma
Honoraria: Genzyme
